First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Subscribe To Our Newsletter & Stay Updated
